WO2001012187A3 - Benzoic acid derivatives and their use as ppar receptor agonists - Google Patents
Benzoic acid derivatives and their use as ppar receptor agonists Download PDFInfo
- Publication number
- WO2001012187A3 WO2001012187A3 PCT/GB2000/003140 GB0003140W WO0112187A3 WO 2001012187 A3 WO2001012187 A3 WO 2001012187A3 GB 0003140 W GB0003140 W GB 0003140W WO 0112187 A3 WO0112187 A3 WO 0112187A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzoic acid
- acid derivatives
- receptor agonists
- ppar receptor
- ppar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00953320A EP1210343A2 (en) | 1999-08-18 | 2000-08-14 | Benzoic acid derivatives and their use as ppar receptor agonists |
MXPA02001598A MXPA02001598A (en) | 1999-08-18 | 2000-08-14 | Chemical compounds. |
JP2001516533A JP2003507327A (en) | 1999-08-18 | 2000-08-14 | Chemical compound |
AU65834/00A AU6583400A (en) | 1999-08-18 | 2000-08-14 | Chemical compounds |
KR1020027002019A KR20020020817A (en) | 1999-08-18 | 2000-08-14 | Chemical Compounds |
IL14782100A IL147821A0 (en) | 1999-08-18 | 2000-08-14 | Benzoic acid derivatives and their use as ppar receptor agonists |
BR0013368-0A BR0013368A (en) | 1999-08-18 | 2000-08-14 | Use of a compound, compound, and pharmaceutical composition |
CA002380775A CA2380775A1 (en) | 1999-08-18 | 2000-08-14 | Benzoic acid derivatives and their use as ppar receptor agonists |
NZ517059A NZ517059A (en) | 1999-08-18 | 2000-08-14 | Indole derivatives of benzoic acid which act as peroxisome proliferator activated receptor (PPAR) |
NO20020765A NO20020765L (en) | 1999-08-18 | 2002-02-15 | Chemical connections |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9919411.0 | 1999-08-18 | ||
GBGB9919411.0A GB9919411D0 (en) | 1999-08-18 | 1999-08-18 | Chemical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001012187A2 WO2001012187A2 (en) | 2001-02-22 |
WO2001012187A3 true WO2001012187A3 (en) | 2001-06-07 |
Family
ID=10859283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/003140 WO2001012187A2 (en) | 1999-08-18 | 2000-08-14 | Benzoic acid derivatives and their use as ppar receptor agonists |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1210343A2 (en) |
JP (1) | JP2003507327A (en) |
KR (1) | KR20020020817A (en) |
CN (1) | CN1379774A (en) |
AU (1) | AU6583400A (en) |
BR (1) | BR0013368A (en) |
CA (1) | CA2380775A1 (en) |
GB (1) | GB9919411D0 (en) |
IL (1) | IL147821A0 (en) |
MX (1) | MXPA02001598A (en) |
NO (1) | NO20020765L (en) |
NZ (1) | NZ517059A (en) |
WO (1) | WO2001012187A2 (en) |
ZA (1) | ZA200200669B (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495949B1 (en) | 1999-11-03 | 2002-12-17 | Orion Electric Co., Ltd. | Electron tube cathode |
US6503907B2 (en) * | 2000-11-28 | 2003-01-07 | Hoffmann-La Roche Inc. | Indole and dihydroindole derivatives |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
US7291639B2 (en) | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
WO2003000253A1 (en) | 2001-06-20 | 2003-01-03 | Wyeth | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
WO2003035602A1 (en) * | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Lipid modulators |
JP2005517008A (en) * | 2002-02-05 | 2005-06-09 | イーライ・リリー・アンド・カンパニー | Urea linker derivatives for use as PPAR modulators |
ES2299702T3 (en) | 2002-06-20 | 2008-06-01 | Astrazeneca Ab | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE. |
SE0201937D0 (en) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
DE60306547T2 (en) | 2002-12-10 | 2007-06-28 | Wyeth | SUBSTITUTED 3-ALKYL AND 3-ARYL ALKYL-1H-INDOL-1-YL-ACETIC ACID DERIVATIVES AS PLASMINOGEN ACTIVATOR |
ES2325071T3 (en) | 2002-12-10 | 2009-08-25 | Wyeth | DERIVATIVES OF INDOL-OXO-ACETILAMINOACETIC ACID REPLACED AS INHIBITORS OF THE PLASMINOGEN-1 ACTIVATOR INHIBITOR (PAI-1). |
AU2003297787A1 (en) | 2002-12-10 | 2004-06-30 | Wyeth | Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
JP2006510673A (en) | 2002-12-10 | 2006-03-30 | ワイス | Aryl, aryloxy and alkyloxy substituted 1H-indol-3-ylglyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor 1 (PAI-1) |
DE10308352A1 (en) * | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Branched side chain arylcycloalkyl derivatives, process for their preparation and their use as medicaments |
TWI289141B (en) | 2003-03-11 | 2007-11-01 | Hoffmann La Roche F. Ag. | Quinolinone derivatives and uses thereof |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
AU2004233941A1 (en) * | 2003-04-25 | 2004-11-11 | H. Lundbeck A/S | Sustituted indoline and indole derivatives |
BRPI0414313A (en) | 2003-09-11 | 2006-11-07 | Kemia Inc | cytokine inhibitors |
US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
EP1781645A1 (en) | 2004-08-23 | 2007-05-09 | Wyeth | Oxazolo-naphthyl acids as plasminogen activator inhibitor type-1(pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases |
WO2006045478A1 (en) * | 2004-10-27 | 2006-05-04 | F. Hoffmann-La Roche Ag | New indole or benzimidazole derivatives |
ATE489138T1 (en) * | 2005-04-13 | 2010-12-15 | Neuraxon Inc | SUBSTITUTED INDOLE COMPOUNDS WITH NOS INHIBITING ACTIVITY |
EP1919866A2 (en) | 2005-08-17 | 2008-05-14 | Wyeth a Corporation of the State of Delaware | Substituted indoles and use thereof |
US8686002B2 (en) | 2005-08-21 | 2014-04-01 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as binding partners for 5-HT5 receptors |
US7989447B2 (en) | 2006-04-13 | 2011-08-02 | Neuraxon, Inc. | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity |
CA2651942A1 (en) | 2006-05-11 | 2008-07-03 | Janssen Pharmaceutica N.V. | 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors |
WO2007134149A2 (en) | 2006-05-11 | 2007-11-22 | Janssen Pharmaceutica N.V. | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors |
US7432255B2 (en) * | 2006-05-16 | 2008-10-07 | Hoffmann-La Roche Inc. | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives |
WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
RU2009136330A (en) | 2007-03-01 | 2011-04-10 | Янссен Фармацевтика Н.В. (Be) | TETRAHYDROISOCHINOLINE COMPOUNDS AS HISTAMIN H3 RECEPTOR MODULATORS |
ES2576643T3 (en) | 2007-03-09 | 2016-07-08 | Second Genome, Inc. | Bicycloheteroaryl compounds as modulators of P2X7 and uses thereof |
WO2009005998A1 (en) * | 2007-07-02 | 2009-01-08 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
FR2921366B1 (en) * | 2007-09-26 | 2009-12-04 | Servier Lab | NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
MX356032B (en) | 2007-11-16 | 2018-04-11 | Neuraxon Inc | Indole compounds and methods for treating visceral pain. |
CA2713519A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Amide derivatives as positive allosteric modulators and methods of use thereof |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
LT3023102T (en) | 2010-11-08 | 2018-09-25 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
CN105287604B (en) | 2010-11-08 | 2019-07-09 | 阿尔比里奥公司 | Pharmaceutical composition containing ibat inhibitor and bile acid binding agent |
WO2012170554A1 (en) | 2011-06-06 | 2012-12-13 | Theodore Mark Kamenecka | N-biphenylmethylindole modulators of pparg |
US9051265B2 (en) * | 2011-06-06 | 2015-06-09 | The Scripps Research Institute | N-benzylindole modulators of PPARG |
US20140315881A1 (en) * | 2011-07-29 | 2014-10-23 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
US9309227B2 (en) | 2011-11-22 | 2016-04-12 | The Scripps Research Institute | N-biphenylmethylbenzimidazole modulators of PPARG |
AU2012358978B2 (en) * | 2011-12-21 | 2017-10-05 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
EP2844247A4 (en) * | 2012-04-20 | 2015-11-25 | Anderson Gaweco | Ror modulators and their uses |
EP2844259A4 (en) | 2012-04-30 | 2015-11-11 | Anderson Gaweco | Ror modulators and their uses |
CN104788358A (en) * | 2014-01-20 | 2015-07-22 | 中国科学院上海药物研究所 | N-(3-fluoro-4-chlorobenzyl)indole derivative and use thereof |
KR101585605B1 (en) * | 2014-03-20 | 2016-01-21 | 현대약품 주식회사 | Compounds that binding with PPARG(Peroxisome Proliferator Activated Receptor-Gamma) but not act as an agonist and pharmaceutical composition for diseases related with PPARG containing the same as an active ingredient |
WO2015161108A1 (en) | 2014-04-16 | 2015-10-22 | The Scripps Research Institute | Pparg modulators for treatment of osteoporosis |
CN107176914B (en) * | 2016-03-09 | 2022-06-28 | 浙江旭晨医药科技有限公司 | GVS series compound and its use |
JP7266538B2 (en) * | 2017-05-26 | 2023-04-28 | 石薬集団中奇制薬技術(石家庄)有限公司 | Lactam compounds as FXR receptor agonists |
KR102242658B1 (en) * | 2018-08-29 | 2021-04-21 | 숙명여자대학교산학협력단 | A substituted indole derivatives, preparation method therof and pharmaceutical composition for use in preventing or treating PPARα, PPARγ and PPARδ related diseases containing the same as an active ingredient |
US11319330B2 (en) * | 2018-09-07 | 2022-05-03 | Medshine Discovery Inc. | Tricyclic furan-substituted piperidinedione compound |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0179619A1 (en) * | 1984-10-19 | 1986-04-30 | Ici Americas Inc. | Heterocyclic amides |
US4894386A (en) * | 1987-04-15 | 1990-01-16 | Ici Americas Inc. | Aliphatic carboxamides |
WO1997005114A1 (en) * | 1995-07-31 | 1997-02-13 | Laboratorios Menarini S.A. | Quinolone sulfonimides having leukotriene-antagonistic action |
EP0780389A1 (en) * | 1995-12-22 | 1997-06-25 | Tobishi Pharmaceutical Co., Ltd. | Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them |
WO1998051667A1 (en) * | 1997-05-16 | 1998-11-19 | Chugai Seiyaku Kabushiki Kaisha | Indole derivatives and mono- and diazaindole derivatives |
US5902726A (en) * | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
-
1999
- 1999-08-18 GB GBGB9919411.0A patent/GB9919411D0/en not_active Ceased
-
2000
- 2000-08-14 IL IL14782100A patent/IL147821A0/en unknown
- 2000-08-14 JP JP2001516533A patent/JP2003507327A/en active Pending
- 2000-08-14 AU AU65834/00A patent/AU6583400A/en not_active Abandoned
- 2000-08-14 KR KR1020027002019A patent/KR20020020817A/en not_active Application Discontinuation
- 2000-08-14 NZ NZ517059A patent/NZ517059A/en unknown
- 2000-08-14 CA CA002380775A patent/CA2380775A1/en not_active Abandoned
- 2000-08-14 MX MXPA02001598A patent/MXPA02001598A/en unknown
- 2000-08-14 WO PCT/GB2000/003140 patent/WO2001012187A2/en active IP Right Grant
- 2000-08-14 BR BR0013368-0A patent/BR0013368A/en not_active IP Right Cessation
- 2000-08-14 EP EP00953320A patent/EP1210343A2/en not_active Withdrawn
- 2000-08-14 CN CN00814336A patent/CN1379774A/en active Pending
-
2002
- 2002-01-24 ZA ZA200200669A patent/ZA200200669B/en unknown
- 2002-02-15 NO NO20020765A patent/NO20020765L/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0179619A1 (en) * | 1984-10-19 | 1986-04-30 | Ici Americas Inc. | Heterocyclic amides |
US4894386A (en) * | 1987-04-15 | 1990-01-16 | Ici Americas Inc. | Aliphatic carboxamides |
US5902726A (en) * | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
WO1997005114A1 (en) * | 1995-07-31 | 1997-02-13 | Laboratorios Menarini S.A. | Quinolone sulfonimides having leukotriene-antagonistic action |
EP0780389A1 (en) * | 1995-12-22 | 1997-06-25 | Tobishi Pharmaceutical Co., Ltd. | Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them |
WO1998051667A1 (en) * | 1997-05-16 | 1998-11-19 | Chugai Seiyaku Kabushiki Kaisha | Indole derivatives and mono- and diazaindole derivatives |
Non-Patent Citations (6)
Title |
---|
BIOORG. MED. CHEM. LETT., vol. 8, no. 21, - 1998, pages 3053 - 3058 * |
CHEMICAL ABSTRACTS, vol. 130, no. 9, 1 March 1999, Columbus, Ohio, US; abstract no. 110138m, HULME, CHRISTOPHER ET AL.: "Orally active indole N-oxide PDE4 inhibitors." XP002158920 * |
DATABASE CHEMICAL ABSTRACTS XP002158921 * |
R GRIERA ET AL.: "Synthesis and pharmacological evaluation of new cysLT1 receptor antagonists", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA., vol. 32, - 1997, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS., FR, pages 547 - 570, XP002158918, ISSN: 0223-5234 * |
ROBERT T. JACOBS ET AL.: "Substituted 3-(phenylmethyl)-1H-indole-5-carboxamides and 1-(phenylmethyl)indole-6-carboxamides as potent, selective, orally active antagonists of the peptidoleukotrienes", JOURNAL OF MEDICINAL CHEMISTRY., vol. 36, no. 3, - 1993, AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 394 - 409, XP002158919, ISSN: 0022-2623 * |
ROBERT T. JACOBS ET AL.: "Synthesis, structure-activity relationships, and pharmacological evaluation of a series of fluorinated 3-benzyl-5-indolecarboxamides: identification of 4-((5-(((2R)-2-methyl-4,4,4,-trifluorobutyl)carbamoyl)-1-methylindol-3-yl)methyl)-3-methoxy-N-((2-methylphenyl)sulfonyl)benzamide, ...", JOURNAL OF MEDICINAL CHEMISTRY., vol. 37, no. 9, - 1994, AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 1282 - 1297, XP002158917, ISSN: 0022-2623 * |
Also Published As
Publication number | Publication date |
---|---|
AU6583400A (en) | 2001-03-13 |
ZA200200669B (en) | 2003-06-25 |
CA2380775A1 (en) | 2001-02-22 |
NZ517059A (en) | 2004-05-28 |
IL147821A0 (en) | 2002-08-14 |
MXPA02001598A (en) | 2002-07-02 |
BR0013368A (en) | 2002-05-07 |
JP2003507327A (en) | 2003-02-25 |
EP1210343A2 (en) | 2002-06-05 |
KR20020020817A (en) | 2002-03-15 |
WO2001012187A2 (en) | 2001-02-22 |
NO20020765D0 (en) | 2002-02-15 |
NO20020765L (en) | 2002-04-17 |
CN1379774A (en) | 2002-11-13 |
GB9919411D0 (en) | 1999-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001012187A3 (en) | Benzoic acid derivatives and their use as ppar receptor agonists | |
HUP0201654A3 (en) | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (ppar) alpha, their preparation and pharmaceutical composition containing the same | |
NZ515902A (en) | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, and type 2 diabetes | |
HK1068870A1 (en) | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | |
AU2804400A (en) | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists | |
NO20020764D0 (en) | Benzoic acid derivatives for the treatment of diabetes mellitus | |
IL175310A0 (en) | Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists | |
BR0211414A (en) | Compound, use thereof, pharmaceutical composition, and methods for treating and / or preventing nuclear receptor-mediated conditions and type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance or obesity | |
NO20052575L (en) | New compounds, their preparation and use | |
HUP0402486A3 (en) | Nitrogen containing heterocyclic compounds as peroxisome proliferator activated receptor agonists, their use and pharmaceutical compositions cointaining them | |
HK1083021A1 (en) | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | |
NZ516290A (en) | Substituted phenoxyacetic acids | |
WO2002044113A3 (en) | Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | |
PL378130A1 (en) | 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis | |
EP1348698A4 (en) | Substituted carboxylic acid derivatives | |
ES2156574A1 (en) | Thiazolidinedione derivatives as antidiabetic agents | |
ATE475642T1 (en) | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS | |
EP1508566A4 (en) | (2s)-2-ethylphenylpropionic acid derivative | |
AU2003238249A1 (en) | USE OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR)-Gamma LIGANDS AS A TREATMENT FOR PITUITARY TUMORS AND ASSOCIATED CONDITIONS, SUCH AS CUSHING'S SYNDROME | |
ES2166406T3 (en) | USE OF 1,5-BENZODIAZEPIN DERIVATIVES FOR THE CONTROL OF GASTRIC EMPTYING IN PATIENTS WITH MELLITUS DIABETES NOT DEPENDENT ON INSULIN. | |
WO2000045894A3 (en) | Use of pyrazole carboxamides | |
IL181010A0 (en) | 2-{3,'2- (phenyl)-oxazol-4-ylmethoxyl-cyclohexylmethoxy}-propionic acid derivatives used as ppar ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes | |
TR199501115A2 (en) | Double rotary oxazole and thiazole substituted ethers. | |
TH67535A (en) | Kyrenoxazole-aryl propionic acid derivative And the use of this substance as PPAR agonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/00669 Country of ref document: ZA Ref document number: 147821 Country of ref document: IL Ref document number: 200200669 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 65834/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000953320 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2380775 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 517059 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/001598 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027002019 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027002019 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008143366 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000953320 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 517059 Country of ref document: NZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000953320 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 517059 Country of ref document: NZ |